Abstract
In the year 2000, an estimated 17 million community-dwelling adults in the United States had daily urinary incontinence (UI), and an additional 33 million suffered from the overlapping condition, overactive bladder. Estimates of the total annual cost of these conditions range up to $32 billion; the largest components are management costs and the expenses associated with nursing home admissions attributable to UI. In most cases, patients with UI can be treated with pharmaceutical agents, in addition to behavioral therapy. Until recently, pharmaceutical therapy for UI has been limited, especially because the adverse effects of available agents resulted in poor adherence to treatment regimens. Recent innovations in molecular design and new dosage forms of UI medications offer the promise of fewer and less severe adverse effects and, thus, better treatment outcomes for patients. Additionally, the availability of multiple agents within a therapeutic class offers health care providers a spectrum of choices with which to personalize treatment for each individual patient. New pharmacologic treatment options for UI have the potential to allow greater independence for older persons who reside at home and to delay or avoid the costs of admission to long-term care facilities. Alternate dosage forms, which include patches and sustained-release formulations, may benefit patients who have difficulty chewing, swallowing, or remembering to take medications. Although these newer products are generally more expensive than older forms of therapy, they typically have more favorable cost-effectiveness ratios. Access to these new medications for patients enrolled in public and private health care plans may help to reduce the economic and social burden of UI care.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society.Am J Obstet Gynecol. 2002;187:116–126.
Thom DH, Haan MN, Van Den Eeden SK. Medically recognized urinary incontinence and risks of hospitalization, nursing home admission and mortality.Age Ageing. 1997;26:367–374.
Optimizing quality of care and cost effectiveness in the treatment of overactive bladder.Am J Manag Care. 2001;7(2 suppl):S43–S45.
Garnett S, Abrams P. The natural history of the overactive bladder and detrusor overactivity: a review of the evidence regarding the long-term outcome of the overactive bladder.J Urol. 2003; 169:843–848.
Hu TW, Wagner TH, Bentkover JD, Leblanc K, Zhou SZ, Hunt T. Costs of urinary incontinence and overactive bladder in the United States: a comparative study.Urology. 2004;63:461–465.
Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States.World J Urol. 2003;20:327–336.
Thom D. Variation in estimates of urinary incontinence prevalence in the community: effects of differences in definition, population characteristics, and study type.J Am Geriatr Soc. 1998; 46:473–480.
Minassian VA, Drutz HP, Al-Badr A. Urinary incontinence as a worldwide problem.Int J Gynaecol Obstet. 2003;82:327–338.
Milsom I, Stewart W, Thuroff J. The prevalence of overactive bladder.Am J Manag Care. 2000; 6(11 suppl):S565-S573.
Garraway WM, Russell EB, Lee RJ, et al. Impact of previously unrecognized benign prostatic hyperplasia on the daily activities of middle-aged and elderly men.Br J Gen Pract. 1993;43:318–321.
Burgio KL, Ives DG, Locher JL, Arena VC, Kuller LH. Treatment seeking for urinary incontinence in older adults.J Am Geriatr Soc. 1994;42:208–212.
Branch LG, Walker LA, Wetle TT, DuBeau CE, Resnick NM. Urinary incontinence knowledge among community-dwelling people 65 years of age and older.J Am Geriatr Soc. 1994;42:1257–1262.
Penning-van Beest FJ, Sturkenboom MC, Bemelmans BL, Herings RM. Undertreatment of urinary incontinence in general practice.Ann Pharmacother. 2005;39:17–21.
Palmer MH, McCormick KA, Langford A, Langlois J, Alvaran M. Continence outcomes: documentation on medical records in the nursing home environment.J Nurs Care Qual. 1992; 6:36–43.
DuBeau CE, Levy B, Mangione CM, Resnick NM. The impact of urge urinary incontinence on quality of life: importance of patients’ perspective and explanatory style.J Am Geriatr Soc. 1998;46:683–692.
Lenderking WR, Nackley JF, Anderson RB, Testa MA. A review of the quality-of-life aspects of urinary urge incontinence.Pharmacoeconomics. 1996;9:11–23.
Grimby A, Milsom I, Molander U, Wiklund I, Ekelund P. The influence of urinary incontinence on the quality of life of elderly women.Age Ageing. 1993;22:82–89.
Noelker LS. Incontinence in elderly cared for by family.Gerontologist. 1987;27:194–200.
Goode PS. Predictors of treatment response to behavioral therapy and pharmacotherapy for urinary incontinence.Gastroenterology. 2004;126(1 suppl 1):S141-S145.
Appell RA. The newer antimuscarinic drugs: bladder control with less dry mouth.Cleve Clin J Med. 2002;69:761, 765–766, 768–769.
Wagner TH, Hu TW. Economic costs of urinary incontinence in 1995.Urology. 1998;51:355–361.
Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with overactive bladder.Am J Manag Care. 2000;6(11 suppl):S574-S579.
Muller N. What Americans understand and how they are affected by bladder control problems: highlights of recent nationwide consumer research.Urol Nurs. 2005;25:109–115.
Wilson L, Brown JS, Shin GP, Luc KO, Subak LL. Annual direct cost of urinary incontinence.Obstet Gynecol. 2001;98:398–406.
Martin CM. Urinary incontinence in the elderly.Consult Pharm. Available at: http:// www.ascp.com/publications/tcp/1997/aug/elderly.html. Accessed September 7, 2006.
Nuotio M, Tammela TL, Luukkaala T, Jylha M. Predictors of institutionalization in an older population during a 13-year period: the effect of urge incontinence.J Gerontol A Biol Sci Med Sci. 2003;58:756–762.
Nygaard I, Thom DH, Calhoun EA. Urinary incontinence in women. In: Nygaard I, Thom DH, Calhoun EA, Litwin MS, Saigal CS, eds.Urologic Diseases in America. Washington, DC: US Government Publishing Office; 2004.
Morrison A, Levy R. Fraction of nursing home admissions attributable to urinary incontinence.Value Health. 2006;9:272–274.
Birnbaum HG, Leong SA, Oster EF, Kinchen K, Sun P. Cost of stress urinary incontinence: a claims data analysis.Pharmacoeconomics. 2004;22:95–105.
Chartbook on Trends in the Health of Americans. United States, 2002. Hyattsville, Md: National Center for Health Statistics; 2002.
Watson NM, Brink CA, Zimmer JG, Mayer RD. Use of the Agency for Health Care Policy and Research urinary incontinence guideline in nursing homes.J Am Geriatr Soc. 2003;51:1779–1786.
Turnbull GB. CMS new guidance to LTC surveyors effective June 27: F315-urinary incontinence and catheters.Ostomy Wound Manage. 2005;51:18–19.
Wound ostomy and continence nurses. Position statement on coverage for pelvic floor biofeedback therapy. Available at: http://www.wocn.org/publications/posstate/biofeedback.html. Accessed September 7, 2006.
Baker DI, Bice TW. The influence of urinary incontinence on publicly financed home care services to low-income elderly people.Gerontologist. 1995;35:360–369.
Brown JS, Vittinghoff E, Wyman JF, et al. Urinary incontinence: does it increase risk for falls and fractures? Study of osteoporotic fractures research group.J Am Geriatr Soc. 2000;48:721–725.
McGhan WF. Cost effectiveness and quality of life considerations in the treatment of patients with overactive bladder.Am J Manag Care. 2001;7(2 suppl):S62-S75.
Yu YF, Nichol MB, Yu AP, Ahn J. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California Medicaid program.Value Health. 2005;8:495–505.
Chapple C, Khullar V, Gabriel Z, Dooley JA. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis.Eur Urol. 2005;48:5–26.
Franks M, Chartier-Kastler E, Chancellor MB. New pharmacologic and minimally invasive therapies for the overactive bladder.Drug Benefit Trends. 2000;12:49–57.
Chapple CR, Martinez-Garcia R, Selvaggia L, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial.Eur Urol. 2005;48:464–470.
Diokno AC, Appell RA, Sand PK, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial.Mayo Clin Proc. 2003;78:687–695.
Staskin DR. Transdermal systems for overactive bladder: principles and practice.Rev Urol. 2003;5(suppl 8):S26-S30.
Zhou Z, Barr C, Torigoe Y, et al. Persistence of therapy with drugs for overactive bladder (abstract).Value Health. 2001;4:161.
Lawrence M, Guay DR, Benson SR, Anderson MJ. Immediate-release oxybutynin versus tolterodine in detrusor overactivity: a population analysis.Pharmacotherapy. 2000;20:470–475.
Chui MA, Williamson T, Arciniego J, et al. Patient persistency with medications for overactive bladder (abstract).Value Health. 2004;7:366.
Noe L, Sneeringer R, Patel B, Williamson T. The implications of poor medication persistence with treatment for overactive bladder.Manag Care Interface. 2004;17:54–60.
Andersson KE. Potential benefits of muscarinic M3 receptor selectivity.Eur Urol Suppl. 2002; 1:23–28.
Andersson KE. Antimuscarinics for treatment of overactive bladder.Lancet Neurol. 2004;3:46–53.
Parsons M, Robinson D, Cardozo L. Darifenacin in the treatment of overactive bladder.Int J Clin Pract. 2005;59:831–838.
Hussain RM, Hartigan-Go K, Thomas SH, Ford GA. Effect of oxybutynin on the QTc interval in elderly patients with urinary incontinence.Br J Clin Pharmacol. 1996;41:73–75.
Garely AD, Burrows L. Benefit-risk assessment of tolterodine in the treatment of overactive bladder in adults.Drug Saf. 2004;27:1043–1057.
Chapple CR, Abrams P. Comparison of darifenacin and oxybutynin in patients with overactive bladder: assessment of ambulatory urodynamics and impact on salivary flow.Eur Urol. 2005; 48:102–109.
Rovner ES. Trospium chloride in the management of overactive bladder.Drugs. 2004;64:2433–2446.
Todorova A, Vonderheid-Guth B, Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system.J Clin Pharmacol. 2001;41:636–644.
Jaffe WI, Te AE. Overactive bladder in the male patient: epidemiology, etiology, evaluation, and treatment.Curr Urol Rep. 2005;6:410–418.
Bolge SC, Cerulli A, Kahler KH, Gause D. Impact of successful treatment of overactive bladder on health care resource use and productivity.Drug Benefit Trends. 2006;18:244–255.
Hughes DA, Dubois D. Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence.Pharmacoeconomics. 2004;22:1047–1059.
Bentkover JD, Chapple C, Corey R, Hill S, Stewart EJ. Adapting a US cost-offset economic model for overactive bladder for the European marketplace (abstract).Value Health. 2000;3:361.
Engqvist H. A new voice for silent sufferers.Scrip. 2005;146:35–37.
Hegde SS, Mammen M, Jasper JR. Antimuscarinics for the treatment of overactive bladder: current options and emerging therapies.Curr Opin Investig Drugs. 2004;5:40–49.
Wertheimer AI, Santella TM, Finestone AJ, Levy RA. Drug delivery systems improve pharmaceutical profile and facilitate medication adherence.Adv Ther. 2005;22:559–577.
Wertheimer AI, Levy R, O’Connor TW. Too many drugs? The clinical and economic value of incremental innovations. In: Farquhar I, Summers K, Sorkin A, eds.Investing in Health: the Social and Economic Benefits of Health Care Innovation. Greenwich, Conn: JAI Press; 2001;14: 77–88.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Levy, R., Muller, N. Urinary incontinence: Economic burden and new choices in pharmaceutical treatment. Adv Therapy 23, 556–573 (2006). https://doi.org/10.1007/BF02850045
Issue Date:
DOI: https://doi.org/10.1007/BF02850045